- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
53 result(s) found for: Anterior uveitis.
Displaying page 1 of 3.
EudraCT Number: 2008-003689-24 | Sponsor Protocol Number: PAVC1012 | Start Date*: 2009-04-29 | |||||||||||
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | |||||||||||||
Full Title: Lotemax in the treatment of chronic anterior uveitis: a pilot study | |||||||||||||
Medical condition: Chronic Anterior Uveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004862-24 | Sponsor Protocol Number: ESBA105CRD04 | Start Date*: 2009-01-02 | |||||||||||
Sponsor Name:ESBATech, an Alcon Biomedical Research Unit LLC | |||||||||||||
Full Title: An open-label exploratory study to assess the safety, tolerability and clinical activity of topically applied ESBA105 in patients with acute anterior uveitis | |||||||||||||
Medical condition: Acute, unilateral anterior uveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006545-13 | Sponsor Protocol Number: LX211-03-UV | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis. | |||||||||||||
Medical condition: Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001609-25 | Sponsor Protocol Number: X052131/CL3-78989-006 | Start Date*: 2013-01-02 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:XOMA (US) LLC | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently C... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PT (Completed) IT (Completed) GR (Prematurely Ended) ES (Completed) PL (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006543-31 | Sponsor Protocol Number: LX211-01-UV | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ... | |||||||||||||
Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016008-22 | Sponsor Protocol Number: M10-880 | Start Date*: 2010-07-19 | |||||||||||||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||||||||||||
Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis | |||||||||||||||||||||||
Medical condition: Inactive non-infectious intermediate-, posterior-, or pan-uveitis. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003243-37 | Sponsor Protocol Number: | Start Date*: 2017-11-02 | |||||||||||||||||||||||||||||||
Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health | |||||||||||||||||||||||||||||||||
Full Title: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial | |||||||||||||||||||||||||||||||||
Medical condition: Uveitic macular oedema | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Temporarily Halted) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016095-68 | Sponsor Protocol Number: M10-877 | Start Date*: 2010-07-19 | |||||||||||||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||||||||||||
Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious... | |||||||||||||||||||||||
Medical condition: Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000304-29 | Sponsor Protocol Number: | Start Date*: 2016-04-05 | |||||||||||||||||||||||||||||||
Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health | |||||||||||||||||||||||||||||||||
Full Title: Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial | |||||||||||||||||||||||||||||||||
Medical condition: Uveitic macular oedema | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001589-15 | Sponsor Protocol Number: BLP 415-007 | Start Date*: 2005-09-15 | |||||||||||
Sponsor Name:Bausch & Lomb Incorporated | |||||||||||||
Full Title: A multi-center study evaluating the safety of a replacement intravitreal fluocinolone acetonide (FA) (0.59 mg) implant in patients with non-infectious posterior uveitis who were previously treated ... | |||||||||||||
Medical condition: Non-infectious Uveitis affecting posterior segment of the eye | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000119-10 | Sponsor Protocol Number: I4V-MC-JAHW | Start Date*: 2019-08-06 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Ch... | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis Associated Uveitis or Anterior Antinuclear Antibody-Positive Uveitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001243-67 | Sponsor Protocol Number: CAIN457A2208 | Start Date*: 2011-07-01 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||||||||||||
Full Title: An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis | |||||||||||||||||||||||
Medical condition: Intermediate, posterior or pan-uveitis of noninfectious origin | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004845-34 | Sponsor Protocol Number: ACT13480 | Start Date*: 2013-09-02 | |||||||||||
Sponsor Name:Sanofi-aventis recherche et développement | |||||||||||||
Full Title: A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients with Non-Infectious, Intermediate, Po... | |||||||||||||
Medical condition: Uveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003254-90 | Sponsor Protocol Number: CLFG316A2204 | Start Date*: 2012-05-14 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||||||||||||
Full Title: A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring s... | ||||||||||||||||||||||||||||
Medical condition: Active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001810-14 | Sponsor Protocol Number: PSV-FAI-001 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:pSivida Corporation | |||||||||||||
Full Title: A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS... | |||||||||||||
Medical condition: chronic non-infectious uveitis affecting the posterior segment of the eye | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004899-50 | Sponsor Protocol Number: 2200/07 | Start Date*: 2008-05-13 | ||||||||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | ||||||||||||||||||
Full Title: OCT analysis of cystoid macular edema in uveitis patients undergoing anti-inflammatory treatment | ||||||||||||||||||
Medical condition: Cystoid macular edema in uveitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001622-29 | Sponsor Protocol Number: ALI-P01-21-006 | Start Date*: 2023-03-01 | |||||||||||
Sponsor Name:Alimera Sciences Europe Limited | |||||||||||||
Full Title: A NON-RANDOMISED, OPEN-LABEL, UNCONTROLLED, MULTI-CENTRE, PHASE IIIB STUDY EVALUATING THE SAFETY AND EFFICACY OF FLUOCINOLONE ACETONIDE 190 MICROGRAMS INTRAVITREAL IMPLANT IN PAEDIATRIC SUBJECTS FR... | |||||||||||||
Medical condition: Non-Infectious Uveitis affecting the posterior segment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006544-66 | Sponsor Protocol Number: LX211-02-UV | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Qu... | |||||||||||||
Medical condition: Subjects with clinically quiescent sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis requiring systemic immune suppression. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015509-38 | Sponsor Protocol Number: CAIN457C2302E1 | Start Date*: 2010-10-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppres... | |||||||||||||
Medical condition: Non-infectious, intermediate uveitis, posterior uveitis or panuveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001595-19 | Sponsor Protocol Number: 32-007 | Start Date*: 2011-11-18 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infec... | |||||||||||||
Medical condition: Uveitis of the Posterior Segment of the Eye. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
